|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:alsoKnownAs
|
gptkb:Stenabolic
|
|
gptkbp:CASNumber
|
1379686-30-2
|
|
gptkbp:category
|
investigational drug
sulfonamide
research chemical
thiazole
chlorobenzene derivative
REV-ERB agonist
performance-enhancing drug (investigational)
|
|
gptkbp:compatibleWith
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:developedBy
|
gptkb:The_Scripps_Research_Institute
|
|
gptkbp:discoveredIn
|
2012
|
|
gptkbp:effect
|
alters circadian rhythm
increases exercise endurance in mice
reduces fat mass in animal studies
|
|
gptkbp:hasMolecularFormula
|
C20H24ClN3O4S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
SR 90003
|
|
gptkbp:legalStatus
|
not approved for human use
|
|
gptkbp:mechanismOfAction
|
REV-ERB agonist
|
|
gptkbp:molecularWeight
|
437.94 g/mol
|
|
gptkbp:relatedTo
|
gptkb:GW501516
gptkb:SR9011
|
|
gptkbp:routeOfAdministration
|
oral
intraperitoneal
|
|
gptkbp:sideEffect
|
unknown in humans
|
|
gptkbp:structureContains
|
chlorobenzene ring
sulfonamide group
thiazole ring
|
|
gptkbp:studiedIn
|
animal models
|
|
gptkbp:target
|
gptkb:REV-ERBα
gptkb:REV-ERBβ
|
|
gptkbp:uses
|
research chemical
potential metabolic modulator
potential performance enhancer
|
|
gptkbp:bfsParent
|
gptkb:SR_90003_(Virginia)
|
|
gptkbp:bfsLayer
|
7
|